Business Wire

VALBIOTIS

Share
VALBIOTIS: Authorization to Launch the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63, to Reduce Type 2 Diabetes Risk Factors

Regulatory News:

VALBIOTIS (FR0013254851 - ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation, for preventing and combating metabolic diseases, announces the favourable opinion issued from the French Ethical Committee (CPP) and the authorization received from the French National Agency for the Safety of Medicines and Health Products (ANSM) to launch the international Phase II/III REVERSE-IT clinical study on TOTUM-63, to reduce Type 2 Diabetes risk factors.

This clinical study primarily aims at confirming the Phase II positive results previously obtained on the reduction of fasting glycemia, a risk factor for developing Type 2 Diabetes, to obtain health claims from American and European authorities. This study is the latest phase of the development of TOTUM-63. TOTUM-63 is an innovative active substance derived from plants, which has already shown metabolic benefits in people with prediabetes. The CPP favourable opinion and the ANSM authorization allow to initiate the enrollments of 600 subjects with prediabetes and untreated Type 2 Diabetes (early stage) in the study.

Pr Samy HADJADJ, Diabetologist and Professor of Endocrinology and Diabetology at Nantes University Hospital , scientific expert of the study, comments: “ From a prevention perspective, it is essential to act on early stages of metabolic imbalance, before the onset of Type 2 Diabetes or early at disease onset. This is the purpose of the REVERSE-IT study, designed and sized to establish the efficacy of this approach. To do so, we will assess the impact of TOTUM-63 on the main metabolic risk factors for developing Type 2 Diabetes, with particular attention to glycemic parameters, abdominal obesity and body weight ”.

Murielle CAZAUBIEL, Member of the Management Board, Director of Development and Medical Affairs at VALBIOTIS, adds: " We are satisfied to receive the CPP favourable opinion and the ANSM authorization to start the REVERSE-IT clinical study, which will complete the development of our active substance TOTUM-63. It is a major clinical study, through its objective and methodology, to validate our approach in the fight against Type 2 Diabetes. With our teams and all our partners at our side, we are now eager to carry it out, to offer all people with prediabetes the opportunity to benefit from it. "

The REVERSE-IT study follows the positive results of the Phase II study on TOTUM-63, for the reduction of Type 2 Diabetes risk factors. These results were published in 2019 (Press releases of July 3 and September 2, 2019 ) and presented during the American Diabetes Association scientific sessions in June 2020. The REVERSE-IT study will take up the same primary endpoint (reduction of fasting blood glucose level), the same tested dose (5g / day) and the same regimen (three times a day during 6 months). It was co-designed with the medical and regulatory teams of Nestlé Health Science, as part of the global strategic partnership signed in February 2020 for the development and marketing of TOTUM-63.

ABOUT TOTUM-63

TOTUM-63 is a unique and patented combination of 5 plant extracts, with high potential to target the physiopathological mechanisms of Type 2 Diabetes.

TOTUM-63 has already been proven safe and effective in healthy human volunteers during a Phase I/II clinical study. The results of the international randomized, placebo-controlled Phase II study showed that TOTUM-63 reduced fasting and 2-hour blood sugar levels, two risk factors for Type 2 Diabetes, in prediabetics compared to placebo. In these subjects, who also had abdominal obesity, TOTUM-63 significantly reduced body weight and waist circumference.

TOTUM-63 benefits from intellectual property granted in the main markets worldwide: Europe (covering 39 countries), the United States, Russia and national phases are underway in more than 20 countries including China, Japan, Brazil, Australia. The ability to produce TOTUM-63 industrially, in compliance to North American and European standards, has been validated. TOTUM-63 already has marketing authorizations related to its status in Europe.

In 2020, VALBIOTIS has signed a global and long-term partnership with Nestlé Health Science for the development and worldwide commercialization of TOTUM-63. This unique partnership in the field of Nutrition Health plans that TOTUM-63 will be put on the market by Nestlé Health Science at a global level, possibly before obtaining a health claim, depending on the areas. It will also provide funding for the latest development stages of TOTUM-63.

ABOUT NESTLE HEALTH SCIENCE

Nestlé Health Science (NHSc), a wholly-owned subsidiary of Nestlé, is a globally recognized leader in the field of nutritional science. At NHSc we are committed to empowering healthier lives through nutrition for consumers, patients and their healthcare partners. We offer an extensive consumer health portfolio of industry-leading medical nutrition, consumer and VMS brands that are science-based solutions covering all facets of health from prevention, to maintenance, all the way through to treatment. Headquartered in Switzerland, NHSc employs over 5’000 people around the world, who are committed to making a difference in people’s lives, for a healthier today and tomorrow.

For more information, please visit: www.nestlehealthscience.com .

ABOUT VALBIOTIS

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.

VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.

Its products are intended to be licensed to players in the health world.

VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).

VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.

Find out more about VALBIOTIS: www.valbiotis.com

Name: Valbiotis
ISIN code: FR0013254851
Mnemonic code: ALVAL

DISCLAIMER

This press release contains forward-looking statements about VALBIOTIS' objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the VALBIOTIS core document, filed with the French Financial Markets Regulator (AMF) on 31 July 2019 (application number R19-030) as well in its supplement approved by the AMF on Octobre 9, 2019. These documents being available on the Company’s website (www.valbiotis.com ). This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wizz Air Tops Major Airline Emissions Rankings2.7.2025 11:00:00 CEST | Press release

Cirium, the aviation analytics company, creates a new transparent standard and ranking for airline CO2 emissions, identifying the best performing airlines in specific categories Wizz Air is the world's most emissions-efficient airline in new rankings released today by Cirium, the aviation analytics firm. The Cirium Flight Emissions Review ranks the top 20 airlines globally, through a consistent benchmark for flight emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702342529/en/ The top 20 Major airlines globally, ranked by lowest CO2/ASK Wizz Air, the Hungary-based ultra-low-cost airline emits an industry low of 53.9 grams of CO₂ per Available Seat Kilometer (ASK)*, followed by Frontier Airlines (54.4 grams) and Pegasus (57.1 grams) according to the report. The rankings provide the aviation industry with verified comparable data on an equal playing field as the sector advances toward Net Zero by 2050 commitments.

L&T Technology Services Chosen by TRATON GROUP as Strategic Engineering Partner in Global R&D Transformation2.7.2025 10:59:00 CEST | Press release

Multi-year collaboration in LTTS’ Mobility segment to drive platform synergies, electrification, and innovation for TRATON GROUP L&T Technology Services (BSE: 540115, NSE: LTTS), today announced that it has been chosen by the TRATON GROUP, one of the world’s leading manufacturers of commercial vehicles, as a strategic engineering partner. This collaboration in LTTS’ Mobility segment will support TRATON’s roadmap to build a unified, future-ready product-development platform that delivers scale, speed, and sustainable mobility solutions worldwide. TRATON is reshaping its global R&D ecosystem to unlock cross-brand synergies while expanding the share of battery-electric vehicles in line with its 2029 profitability and sustainability targets. LTTS’ selection will see the company provide engineering support, from mechanical and software engineering to digital systems integration - across key development hubs in Sweden, Germany, the United States, Poland, and India. The collaboration position

Nexo Becomes First-Ever Digital Wealth Platform of the DP World Tour, Launches Nexo Championship2.7.2025 10:30:00 CEST | Press release

Named Official Digital Wealth Platform of the DP World Tour through 2027 Nexo becomes Title Partner of the Nexo Championship, which takes place at Trump International Golf Links in August 2025 Nexo, the premier digital assets wealth platform, has signed a three-year landmark partnership with the DP World Tour, becoming an Official Marketing Partner and the Tour’s Official Digital Wealth Platform through 2027. This agreement marks the first-ever multi-year partnership between a digital assets company and a major global golf tour — a historic convergence of crypto and golf — reflecting both organizations’ shared commitment to performance, innovation, and a global outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702770847/en/ Nexo becomes the first-ever Official Digital Wealth Platform of the DP World Tour. Nexo has also become the Title Partner of the newly renamed Nexo Championship — previously the Scottish Champion

Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta2.7.2025 10:00:00 CEST | Press release

Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing for Rekovelle® (follitropin delta); alongside its existing unique algorithm-based dosing Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) gonadotrophin-releasing hormone (GnRH) antagonist protocol cycles. This is the key finding of a trial presented today at the European Society of Human Reproduction and Embryology (ESHRE) Congress in Paris and published in Human Reproduction. These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications.1,2 The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 wome

Germany’s Largest Public Insurer Versicherungskammer Selects Clearwater Analytics for Scalable Investment Operations2.7.2025 09:00:00 CEST | Press release

Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced that Versicherungskammer Group has selected Clearwater Analytics’ platform to power their middle, back office and risk functions. This decision is based on a comprehensive operating model review that began in 2024, followed by a structured selection process to identify a strategic partner. The rigorous assessment underscored the need for change, as market developments and demographic shifts demanded more agility, transparency, and efficiency. By adopting Clearwater’s modern, cloud-based platform, Versicherungskammer will gain real-time, advanced data analytics to strengthen investment decision-making and drive improved performance. This will allow Versicherungskammer to focus on its core competencies in capital investment in the future. “Partnering with Clearwater marks an important shift in our investment operations strategy and is central to our goal of future-proo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye